Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer

2014-08-26 22:49:44 | BioPortfolio


Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Prostate Cancer


Urology Clinic & Prostate Centre, St. Joseph's Hospital, St. Joseph's Health Care London
N6A 4V2




Lawson Health Research Institute

Results (where available)

View Results


Published on BioPortfolio: 2014-08-26T22:49:44-0400

Clinical Trials [1308 Associated Clinical Trials listed on BioPortfolio]

Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer

RATIONALE: Vitamin E supplements may stop or delay the development of prostate cancer in patients who are at risk of prostate cancer or who have prostate cancer. It is not yet known which ...

Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer

This study is for men who have prostate cancer that has spread outside of the prostate gland and is no longer responding to hormone removal therapy. This study is designed to determine if...

Characterization of Prostate Cancer With 3T MR

The long-term goal of this proposal is to provide a pre-treatment evaluation that can assist in the rational selection of patients to undergo appropriate and definitive therapy for prostat...

Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program

There is controversy concerning the preferred treatment for men with localized prostate cancer with regard to the relative effectiveness of different treatments in controlling the cancer a...

Prostate Cancer Utilities and Cost-Effectiveness Analysis

The purpose of this study is to help doctors and patients make better decisions about prostate cancer treatment. This research is being done because we do not know how patient preferences ...

PubMed Articles [13811 Associated PubMed Articles listed on BioPortfolio]

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.

We previously found that inflammation in benign prostate tissue is associated with an increased odds of prostate cancer, especially higher-grade disease. Since part of this link may be due to genetics...

Testosterone replacement therapy and prostate cancer: the downfall of a paradigm?

For six decades, it has been a part of the conventional medical wisdom that higher levels of testosterone increase the risk of prostate cancer. This belief is mostly derived from the well-documented r...

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.

Compelling and long-standing data suggest that androgens play an important role in the development of both normal prostate epithelium and prostate cancer. Although testosterone administration can indu...

Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.

In the Prostate Cancer Prevention Trial (PCPT), finasteride reduced the risk of prostate cancer by 25%, even though high-grade prostate cancer was more common in the finasteride group. However, it rem...

Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomes.

Prostate cancer is the most commonly diagnosed cancer in men in the US, and the second most prevalent cancer in men worldwide. High incidence and survival rates for prostate cancer have resulted in a ...

Medical and Biotech [MESH] Definitions

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.

Tumors or cancer of the PROSTATE.

More From BioPortfolio on "Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer"


Relevant Topic

Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Searches Linking to this Trial